Addressing the complex issues of manufacturing protocols, safety controls, and testing of formulations to meet the strict Saudi FDA standards is a critical component of the DDC operational platform and integral to its long-term success.

DDC started to prepare its drug files from 2019 to now with the toll manufacturing plan for 2025 all of which will be submitted to the Saudi FDA Authority. DDC is coordinating planning with SFDA.

The detailed project completion, manufacturing, and safety protocols of each stage are covered in the due diligence activity.

Investor(s) will have the right to conduct a due diligence exercise on the DDC business model after signing a Memorandum of Understanding and Non-Disclosure Agreements.